Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12313541 | 0.87 | MAOB (0.37) | MAOBTSHREDNRAGSK3BBACE1 | |
| SCHEMBL2463713 | 0.84 | MAOB (0.43) | MAOBTSHREDNRAGSK3BBACE1 | |
| SCHEMBL2355756 | 0.84 | AKR1C3 (0.38) | TSHRGCKMEN1KMT2AALDH1A1 | |
| SCHEMBL12337535 | 0.82 | CYP3A4 (0.40) | L3MBTL1 | |
| SCHEMBL2469681 | 0.81 | IRAK4 (0.37) | IRAK4KMT2AALDH1A1 | |
| SCHEMBL12313531 | 0.77 | PKM (0.48) | MAOBTSHREDNRAGSK3BBACE1 | |
| SCHEMBL2352357 | 0.77 | MAOB (0.57) | MAOBEDNRAGSK3BBACE1MCL1 | |
| SCHEMBL31480852 | 0.73 | TSHR (0.58) | TSHRCETPALDH1A1LMNA | |
| SCHEMBL31480813 | 0.73 | TSHR (0.58) | TSHRCETPALDH1A1LMNA | |
| SCHEMBL2354036 | 0.72 | INPPL1 (0.43) | MAOBIRAK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348859-B1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8354454-B2 | Prodrugs of oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
| EP-2348859-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010039474-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | CETP, SLCO2B1, OXA1L | MAOB 1069/4885TSHR 3227/4885EDNRA 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.